共 311 条
[1]
Coiffier B(2010)Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2040-2045
[2]
Thieblemont C(2017)Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma J Clin Oncol 35 3529-3537
[3]
Van Den Neste E(2015)Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v116-125
[4]
Lepeu G(2017)Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood 130 1800-1808
[5]
Plantier I(2011)Relapsed/refractory diffuse large B-cell lymphoma Hematol Am Soc Hematol Educ Program 2011 498-505
[6]
Castaigne S(2018)The promise of CAR T-cell therapy in aggressive B-cell lymphoma Best Pract Res Clin Haematol 31 293-298
[7]
Lefort S(2015)Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Lancet Oncol 16 704-715
[8]
Marit G(2020)Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 38 155-165
[9]
Macro M(2019)POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL J Clin Oncol 37 TPS7571-361
[10]
Sebban C(2011)Inter-ethnic differences–how important is it in cancer treatment? Ann Acad Med Singapore 40 356-631